KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme (CME) Asset Writedowns and Impairment (2016 - 2021)

Historic Asset Writedowns and Impairment for Cme (CME) over the last 6 years, with Q4 2021 value amounting to -$600000.0.

  • Cme's Asset Writedowns and Impairment rose 4545.45% to -$600000.0 in Q4 2021 from the same period last year, while for Sep 2021 it was -$500000.0, marking a year-over-year decrease of 10182.48%. This contributed to the annual value of $26.3 million for FY2020, which is 5695.58% down from last year.
  • Latest data reveals that Cme reported Asset Writedowns and Impairment of -$600000.0 as of Q4 2021, which was up 4545.45% from $100000.0 recorded in Q3 2021.
  • In the past 5 years, Cme's Asset Writedowns and Impairment ranged from a high of $39.5 million in Q3 2019 and a low of -$9.5 million during Q4 2018
  • For the 4-year period, Cme's Asset Writedowns and Impairment averaged around $7.9 million, with its median value being $500000.0 (2021).
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first skyrocketed by 31578.95% in 2019, then plummeted by 10126.58% in 2020.
  • Cme's Asset Writedowns and Impairment (Quarter) stood at -$9.5 million in 2018, then skyrocketed by 515.79% to $39.5 million in 2019, then crashed by 102.78% to -$1.1 million in 2020, then surged by 45.45% to -$600000.0 in 2021.
  • Its Asset Writedowns and Impairment stands at -$600000.0 for Q4 2021, versus $100000.0 for Q3 2021 and $500000.0 for Q1 2021.